Navigation Links
Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
Date:2/22/2010

Revenue $21 $28 $101 $111 Operating expenses: Research and development 19,974 10,755 61,586 50,086 General and administrative 16,430 4,783 38,556 20,503 ------ ----- ------ ------ Total operating expenses 36,404 15,538 100,142 70,589 ------ ------ ------- ------ Loss from operations (36,383) (15,510) (100,041) (70,478) Interest income 239 712 964 3,619 Interest expense (390) (1,161) (2,321) (5,156) Gain (Loss) from valuation of warrant liability 4,025 7,122 (118,763) 371 ----- ----- -------- --- Net loss ($32,509) ($8,837) ($220,161) ($71,644) ======== ======= ========= ======== Basic and diluted net loss per share ($0.28) ($0.09) ($2.04) ($0.79) ====== ====== ====== ======
'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
2. Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
3. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
4. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
5. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
6. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
7. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
8. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
9. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
10. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
11. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
(Date:12/22/2014)... , Dec. 22, 2014  ConvaTec, a privately-held ... Moraviec has been appointed Interim Chief Executive Officer of ... Moraviec succeeds Ken Berger .  "The Board of ... in leading ConvaTec over the past three years," said ... of Directors.  "We are confident that the company is ...
(Date:12/22/2014)... ALTO, Calif. , Dec, 22, 2014 /PRNewswire/ ... a Phase 2a study of lonafarnib in patients ... study was conducted at the National Institutes of ... Maryland .  The double-blinded, randomized, placebo-controlled, dose ... mg twice daily and 200 mg twice daily ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Astellas Pharma Inc. (Tokyo:4503, "Astellas") announced today that ... 1] , which will further reinforce the company,s commitment to ... world. "We are committed to adopting the Global ... culture and day-to-day operations of our company and through Astellas, ...
... 2011 Watson Pharmaceuticals, Inc. (NYSE: WPI ... filed an Abbreviated New Drug Application (ANDA) with the ... market rivastigmine transdermal system patches, 4.6 mg/24 hr and ... a generic version of Novartis, Exelon(R) Patch. Exelon(R) is ...
Cached Medicine Technology:Astellas Signs United Nations Global Compact 2Astellas Signs United Nations Global Compact 3Watson Confirms Exelon(R) Patent Challenge 2Watson Confirms Exelon(R) Patent Challenge 3
(Date:12/22/2014)... 2014 International efforts to ... epidemic are receiving further support from recent ... organizations (NGOs) and other charitable organizations. While ... emergency responders, patients and others can immediately ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... 2014 The Bob Woodruff Foundation ... invested more than $5 million in programs and ... their families. , This includes $1.3 million in ... helping with: veteran entrepreneurship; community impact; vocational training; ... severely injured veterans. , “The needs of those ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Give a ... season, the gift of health and vitality. , For ... its three top-selling anti-aging formulas in special Holiday Wellness ... rush delivery. , Each bottle contains cutting-edge, proven ... that don't work as well as we age. ...
(Date:12/22/2014)... York NY (PRWEB) December 22, 2014 ... that a federal panel of judges has granted a ... in the U.S. District Court, Eastern District of ... issued an order on December 12 to transfer over ... in 22 districts to the Louisiana court for consolidation ...
(Date:12/22/2014)... December 22, 2014 Christmas is days away, ... a fast and easy solution that will please: the ... be purchased from from $25 up to $350," says Kathy ... customer satisfaction and a wide array of skin care products ... and no expiration dates. , Gift delivery past shipping ...
Breaking Medicine News(10 mins):Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4
... separated at the time of diagnosis do not live as ... the conclusion of a new study to be published in ... peer-reviewed journal of the American Cancer Society. The authors of ... with marital separation may compromise an individual,s immune system and ...
... A new technique may help clinicians hone in on a ... cause. The study, led by principal investigator Y.C. ... the American Thoracic Society,s American Journal of Respiratory and ... of fluid in the pleural cavity, can be maddeningly difficult ...
... Pulmonary Fibrosis is not much better than a death ... is less than three years. But researchers at ... a novel gene utilizing genetic and pharmacologic strategies was ... be developed for future testing in humans. The ...
... works best , SUNDAY, Aug. 23 (HealthDay News) -- Medics ... activity when trying to save a person who,s had a ... defibrillation to restart the heart. , But studies now show ... as ordinary cardiopulmonary resuscitation, or CPR. And what,s more, those ...
... ... facility, positioning the company to support defense-related semiconductor manufacturing and development programs. , ... Cherry Hill, NJ (PRWEB) ... Arms Regulations) registered for its Cherry Hill, New Jersey manufacturing facility. ITAR regulates the ...
... root, study finds , FRIDAY, Aug. 21 (HealthDay News) -- ... before they take root in the brain. , That,s the ... rats -- assuming the findings can be applied to humans, ... of Rio Grande do Sul, Brazil, with colleagues at the ...
Cached Medicine News:Health News:Cancer patients who are separated when diagnosed have worse survival rates 2Health News:New technique can help diagnose mesothelioma 2Health News:U-M researchers discover therapeutic target that could help patients with pulmonary fibrosis 2Health News:It's Back to Basics to Save a Life 2Health News:It's Back to Basics to Save a Life 3Health News:International Micro Industries (IMI) is ITAR Registered 2Health News:Dopamine Lets Bad Experiences Linger 2Health News:Dopamine Lets Bad Experiences Linger 3
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Ethicon Endo-Surgery provides disposable handheld instruments that provide reliable, precise performance every time. Our handheld instruments come in 5mm and 10mm sizes....
... The Auto Suture™ ... inclusive of five (5) ... application in a variety ... urologic, colorectal and other ...
The ENDO MINI-RETRACT™ 5 mm instrument has application in a variety of gynecologic, abdominal, urologic, thoracic and endoscopic procedures for temporary retraction of tissue and small tubular ...
Medicine Products: